Pharmasimple sells its two online drug sales platforms – 06/12/2022 at 10:34


(AOF) – Pharmasimple announces the continuation of its transformation plan with the sale of its two e-commerce platforms pharmasimple.com and parapharmazen.com, having taken the decision to withdraw from the online distribution market for parapharmacy. The company claims that the operation of e-commerce sites no longer offers the level of profitability in line with its expectations, due to a model of very high fixed costs and too much pressure on prices. of sale.

This divestment, combined with a restructuring plan necessary for its sustainability, allows Pharmasimple to reduce its workforce from 65 to 13, excluding physical points of sale, and has led the company to take out a lease for new premises more suited to its new size. .

The Group is also in discussion to seal the fate of its subsidiary Enova Santé, operating the 1001pharmacies.com site.

AOF – LEARN MORE

Find out more about the “pharmacy” sector

Loss of speed in European research

European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.



Source link -86